Role of the thymus in donor specific hyporesponsiveness induced by retroviral transduction of bone marrow using an MHC class I gene

1997 ◽  
Vol 29 (1-2) ◽  
pp. 1133 ◽  
Author(s):  
H. Hayashi ◽  
R.S. Mayfield ◽  
T. Sawada ◽  
S. Germana ◽  
M. Sykes ◽  
...  
2017 ◽  
Vol 69 (8-9) ◽  
pp. 511-519 ◽  
Author(s):  
Zachary A. Silver ◽  
David I. Watkins

2021 ◽  
Vol 12 ◽  
Author(s):  
Cesidio Giuliani ◽  
Sara Verrocchio ◽  
Fabio Verginelli ◽  
Ines Bucci ◽  
Antonino Grassadonia ◽  
...  

In previous studies we have demonstrated that the expression of the Major Histocompatibility Complex (MHC) class I gene in thyrocytes is controlled by several hormones, growth factors, and drugs. These substances mainly act on two regions of the MHC class I promoter a “tissue-specific” region (−800 to −676 bp) and a “hormone/cytokines-sensitive” region (−500 to −68 bp). In a previous study, we have shown that the role of the “tissue-specific” region in the MHC class I gene expression is dominant compared to that of the “hormone/cytokines-sensitive” region. In the present report we further investigate the dominant role of the “tissue-specific” region evaluating the effect of thyroid stimulating hormone (TSH), methimazole (MMI), phenylmethimazole (C10), glucose and thymosin-α1. By performing experiments of electrophoretic mobility shift assays (EMSAs) we show that TSH, MMI and C10, which inhibit MHC class I expression, act on the “tissue-specific” region increasing the formation of a silencer complex. Glucose and thymosin-α1, which stimulate MHC class I expression, act decreasing the formation of this complex. We further show that the silencer complex is formed by two distinct members of the transcription factors families activator protein-1 (AP-1) and nuclear factor-kB (NF-kB), c-jun and p65, respectively. These observations are important in order to understand the regulation of MHC class I gene expression in thyroid cells and its involvement in the development of thyroid autoimmunity.


Science ◽  
1993 ◽  
Vol 260 (5112) ◽  
pp. 1320-1322 ◽  
Author(s):  
T. Howcroft ◽  
K Strebel ◽  
M. Martin ◽  
D. Singer

2000 ◽  
Vol 51 (6) ◽  
pp. 491-495 ◽  
Author(s):  
A. Sato ◽  
Holger Sültmann ◽  
Werner E. Mayer ◽  
Jan Klein

1990 ◽  
Vol 31 (5-6) ◽  
pp. 405-409 ◽  
Author(s):  
Guido Kroemer ◽  
Rima Zoorob ◽  
Charles Auffray

Blood ◽  
1991 ◽  
Vol 78 (2) ◽  
pp. 524-532 ◽  
Author(s):  
RA Zeff ◽  
YF Zhao ◽  
R Tatake ◽  
H Lachman ◽  
F Borriello ◽  
...  

Abstract Numerous tumor cell lines of leukemic origin are known to modulate cell surface expression of major histocompatibility complex (MHC) class I antigens resulting in alterations in their immune detection and tumorigenicity. We have been studying the mechanisms responsible for attenuation of MHC class I gene expression in an H-2 heterozygous (H-2b x H-2d) Abelson-Murine leukemia virus (A-MuLV)-transformed leukemic cell line (designated R8). Here we report that treatment of the R8 cell line with the protein synthesis inhibitor cycloheximide (CHX) increased H-2Kb steady-state messenger RNA (mRNA) levels several fold. The induced H-2Kb mRNA transcripts were functional, as demonstrated by their ability to be translated into immunoprecipitable H-2Kb alloantigen. H-2Kb null variants derived from the R8 cell line were shown to be the product of both cis- and trans-acting mechanisms, insomuch as the treatment of R8-derived H-2Kb non-expressor lines with CHX re-established expression of H-2Kb mRNA to the same extent as transfection of the variant cell line with the wild-type H-2Kb gene. Such findings indicate that downregulation of MHC class I gene expression is constitutive for the R8 leukemic cell line, a phenomenon that may be related to the immature pre-B-cell phenotype of this A-MuLV transformant.


2002 ◽  
Vol 3 (1) ◽  
pp. 20-24 ◽  
Author(s):  
D Lio ◽  
C R Balistreri ◽  
G Colonna-Romano ◽  
M Motta ◽  
C Franceschi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document